Auxilium Sees Slow But Steady Progress With Xiaflex Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Eleven-step process including physician training for administration and reimbursement involved in the drug's uptake.
You may also be interested in...
Auxilium Revamps Commercial Strategy For Xiaflex
The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.
Auxilium Widened Claims For Dupuytren's Contracture Drug Xiaflex, FDA Says
Auxilium Pharmaceuticals' eagerness to draw attention to its new therapy for Dupuytren's disease, rather than any competitive pressure, has resulted in a speedy FDA "untitled" letter for a Xiaflex promotion
Auxilium's Xiaflex Clears FDA With REMS To Educate Doctors On Safe Injection Techniques
REMS does not restrict type of physician who can administer the collagenase enzyme, which will launch in March.